Nuvation Bio Inc. Net Fee Amt
Nuvation Bio Inc. (NUVB) had Net Fee Amt of $39.70 thousand as of 2026-06-26, per its 424B5 filed 2026-06-29.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-29
- 2026-06-26: Net Fee Amt $39.70K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-26 | $39.70K 424B5 · filed 2026-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |